Researchmoz added Most up-to-date research on "Global Hemophilia Market: Industry Analysis & Outlook (2017-2021)" to its huge collection of research reports.
The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes abnormal bleeding with poor clotting. It is classified into hemophilia A, hemophilia B, hemophilia C, and hemophilia with inhibitors.
Treatment for hemophilia is done via replacement therapy, prophylactic therapy, on-demand therapy, gene therapy and many others. Gene therapy is being regarded as an attractive option for treatment of hemophilia. By the year 2030, the pharmaceutical companies are expected to launch their gene therapy treatment for hemophilia, and this might affect the market dynamics at large.
The growth factors of the hemophilia market include increased focus on prophylactic treatment, growing market for FVIII, increasing diagnosis rate, and increasing healthcare expenditure. Major trends of the market include development of novel hemophilia treatment, subcutaneous dosing and growing popularity of gene therapy. Further, growth prospects are hindered by high cost of therapy and consumer’s reluctance in switching to new therapy
options.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1064504
The report offers an in-depth analysis of the global hemophilia market. It also covers the global as well as regional aspect of the market. The top notch players in the market exhibit a very close competition. The report profiles Pfizer Inc., Bayer Group, Shire PLC, and Novo Nordisk.
Table of Content
1. Market Overview1.1 Hemophilia
1.2 Types of Hemophilia
1.3 Signs & Symptoms
1.4 Diagnosis & Treatment
2. Global Market Analysis
2.1 Global Hemophilia Market by Value
2.2 Global Hemophilia Market Forecast by Value
2.3 Global Hemophilia Market by Therapeutic Class
2.3.1 Global Hemophilia Traditional Factors Market Forecast by Value
2.4 Global Hemophilia Market by Type
2.4.1 Global Hemophilia A Market Forecast by Value
2.4.2 Global Hemophilia A Market Forecast by Therapeutic Class
2.4.3 Global Hemophilia A Market by Severity
2.4.4 Global Hemophilia with Inhibitors Market Forecast by Value
2.4.5 Global Hemophilia B Market Forecast by Value
2.4.6 Global Hemophilia B Market Forecast by Therapeutic Class
2.4.7 Global Hemophilia B Market by Severity
3. Regional Market Analysis
3.1 The US
3.1.1 The US Hemophilia Market by Value
3.1.2 The US Hemophilia Market Forecast by Value
3.1.3 The US Hemophilia Market by Type
3.1.4 The US Hemophilia A Market Forecast by Value
3.1.5 The US Hemophilia A Market-Treated Patient Volume Forecast
3.1.6 The US Hemophilia A Market-Pediatric Patients Volume Forecast
3.1.7 The US Hemophilia A Market- Adult Patients Volume Forecast
3.1.8 The US Hemophilia B Market Forecast by Value
3.1.9 The US Hemophilia B Market-Treated Patient Volume Forecast
3.2 Europe
3.2.1 Europe’s Hemophilia Market- Patient Volume Forecast
3.2.2 Europe’s Hemophilia A Market- Patient Volume Forecast
3.2.3 Europe’s Hemophilia B Market- Patient Volume Forecast
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increased Focus on Prophylactic Treatment
4.1.2 Growing Market for FVIII
4.1.3 Increasing Diagnosis Rate
4.1.4 Increasing Healthcare Expenditure
4.2 Key Trends
4.2.1 Development of Novel Hemophilia Treatments
4.2.2 Subcutaneous Dosing
4.2.3 Increasing Demand for Recombinant Versions of Factor VIII & FIX Drugs
4.2.4 Popularity of Gene Therapy
4.3 Challenges
4.3.1 High Cost of Treatment
4.3.2 Reluctance to Switch to New Therapies
5. Competitive Landscape
5.1 Global Hemophilia Market
5.1.1 Revenue and Market Cap Comparison
5.2 Global Hemophilia A Market
5.2.1 Market Share
5.2.2 Factor VIII Products Market Share
5.2.3 Factor VIII Gene Therapy Market Share Forecast
5.3 Global Hemophilia B Market
5.3.1 Market Share
5.3.2 Factor IX Products Market Share Forecast
5.3.3 Factor IX Gene Therapy Market Share Forecast
6. Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Bayer Group
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Shire PLC
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Novo Nordisk
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1064504
The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes abnormal bleeding with poor clotting. It is classified into hemophilia A, hemophilia B, hemophilia C, and hemophilia with inhibitors.
Treatment for hemophilia is done via replacement therapy, prophylactic therapy, on-demand therapy, gene therapy and many others. Gene therapy is being regarded as an attractive option for treatment of hemophilia. By the year 2030, the pharmaceutical companies are expected to launch their gene therapy treatment for hemophilia, and this might affect the market dynamics at large.
The growth factors of the hemophilia market include increased focus on prophylactic treatment, growing market for FVIII, increasing diagnosis rate, and increasing healthcare expenditure. Major trends of the market include development of novel hemophilia treatment, subcutaneous dosing and growing popularity of gene therapy. Further, growth prospects are hindered by high cost of therapy and consumer’s reluctance in switching to new therapy
options.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1064504
The report offers an in-depth analysis of the global hemophilia market. It also covers the global as well as regional aspect of the market. The top notch players in the market exhibit a very close competition. The report profiles Pfizer Inc., Bayer Group, Shire PLC, and Novo Nordisk.
Table of Content
1. Market Overview1.1 Hemophilia
1.2 Types of Hemophilia
1.3 Signs & Symptoms
1.4 Diagnosis & Treatment
2. Global Market Analysis
2.1 Global Hemophilia Market by Value
2.2 Global Hemophilia Market Forecast by Value
2.3 Global Hemophilia Market by Therapeutic Class
2.3.1 Global Hemophilia Traditional Factors Market Forecast by Value
2.4 Global Hemophilia Market by Type
2.4.1 Global Hemophilia A Market Forecast by Value
2.4.2 Global Hemophilia A Market Forecast by Therapeutic Class
2.4.3 Global Hemophilia A Market by Severity
2.4.4 Global Hemophilia with Inhibitors Market Forecast by Value
2.4.5 Global Hemophilia B Market Forecast by Value
2.4.6 Global Hemophilia B Market Forecast by Therapeutic Class
2.4.7 Global Hemophilia B Market by Severity
3. Regional Market Analysis
3.1 The US
3.1.1 The US Hemophilia Market by Value
3.1.2 The US Hemophilia Market Forecast by Value
3.1.3 The US Hemophilia Market by Type
3.1.4 The US Hemophilia A Market Forecast by Value
3.1.5 The US Hemophilia A Market-Treated Patient Volume Forecast
3.1.6 The US Hemophilia A Market-Pediatric Patients Volume Forecast
3.1.7 The US Hemophilia A Market- Adult Patients Volume Forecast
3.1.8 The US Hemophilia B Market Forecast by Value
3.1.9 The US Hemophilia B Market-Treated Patient Volume Forecast
3.2 Europe
3.2.1 Europe’s Hemophilia Market- Patient Volume Forecast
3.2.2 Europe’s Hemophilia A Market- Patient Volume Forecast
3.2.3 Europe’s Hemophilia B Market- Patient Volume Forecast
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increased Focus on Prophylactic Treatment
4.1.2 Growing Market for FVIII
4.1.3 Increasing Diagnosis Rate
4.1.4 Increasing Healthcare Expenditure
4.2 Key Trends
4.2.1 Development of Novel Hemophilia Treatments
4.2.2 Subcutaneous Dosing
4.2.3 Increasing Demand for Recombinant Versions of Factor VIII & FIX Drugs
4.2.4 Popularity of Gene Therapy
4.3 Challenges
4.3.1 High Cost of Treatment
4.3.2 Reluctance to Switch to New Therapies
5. Competitive Landscape
5.1 Global Hemophilia Market
5.1.1 Revenue and Market Cap Comparison
5.2 Global Hemophilia A Market
5.2.1 Market Share
5.2.2 Factor VIII Products Market Share
5.2.3 Factor VIII Gene Therapy Market Share Forecast
5.3 Global Hemophilia B Market
5.3.1 Market Share
5.3.2 Factor IX Products Market Share Forecast
5.3.3 Factor IX Gene Therapy Market Share Forecast
6. Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Bayer Group
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Shire PLC
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Novo Nordisk
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1064504
No comments:
Post a Comment